Previous studies have found that people on long-term treatment for psychotic illnesses have lower cancer rates.
News
Ligelizumab continues to trump Xolair in chronic spontaneous urticaria
The Novartis drug can bind to IgE with an 88-fold higher affinity than Xolair.
Bayer, Evotec join forces on polycystic ovary syndrome
The companies initially linked up for women’s health indications in 2012.
Emergex completes £8.4m Series A vaccines funding
The risk posed by infectious diseases is “greater than ever before”.
Just 2 weeks left to enter the 2020 International Clinical Researcher of the Year
Entry for the 2020 International Clinical Researcher of the Year competition will be closing on the 23rd of January.
New recommendations could get innovative treatments to cancer patients quicker
Complex Innovative Design trials are increasingly being used as an evaluation method by researchers instead of traditional drug development pathways
‘Urgent changes’ needed to avert health research ‘crisis’
Just 0.4% of GPs and 0.1% of nursing, midwifery and other health professionals had research as part of their role in 2017.
Eyesight leaders urge government to address ‘1:20 funding gap’
Back in October 2019 a WHO World Vision Report found that more than one billion people worldwide are living with sight loss, which is contributed to by a lack of investment in eye care and research.
AZ brings MiNA on board to fight metabolic diseases
The partnership is set to combine MiNA’s “leading expertise” with AstraZeneca’s experience in identifying and bringing breakthrough treatments to patients with metabolic diseases.
Galen takes over POA Pharma, expands reach
Galen first signed a distribution agreement with POA back in April 2016.
Improve brand and batch number recording, urge drug safety professionals
A new study revealed that doctors and nurses only recorded batch numbers for biologic medicines between 38% and 58% of the time.
Keytruda misses key lung cancer survival endpoint
The drug significantly improved progression-free survival, but missed its overall survival endpoint.
Merck’s Bavencio hits targets in bladder cancer interim analysis
Last year the drug disappointed in the Phase III JAVELIN Gastric 100 study, but has pulled itself back with new urothelial carcinoma data.
MSD enlists Otsuka units Taiho and Astex to develop KRAS therapies
KRAS therapies had their break-out moment in 2019, with Amgen’s KRAS inhibitor becoming the first drug of its type to post clinical data last September, demonstrating that it shrank tumors in 90% of lung cancer patients.
AZ scores Priority Review with Farxiga
The US FDA accepted a supplemental New Drug Application for the treatment.
